Phaseline

Targets › P2RY12

P2RY12 (P2Y purinoceptor 12): drug programs, companies and trials

28 programs from 23 companies in 37 trials: 21 Phase 4, 9 Phase 3, 6 Phase 2, 1 Phase 1; Cardiovascular, Neurology, Immunology; next expected readout Dec 2026.

Receptor for ADP and ATP coupled to G proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation. (UniProt, Q9H244)

Open in Phaseline: the race on P2RY12, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
VA Office of Research and DevelopmentClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 4Silent Brain InfarctionDec 2026
Seoul National University Bundang HospitalClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 4Type 2 Diabetes; Cardiac EventDec 2026
University of FloridaPrasugrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 4Coronary Artery Disease; Coronary Arterial Disease (CAD)Dec 2026
University of FloridaTicagrelor
Purinergic receptor P2Y12 negative allosteric modulator
P2RY12Phase 4Coronary Artery Disease; Intracranial ArteriosclerosisDec 2026
University of FloridaClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 4Coronary Artery DiseaseJan 2027
University of FloridaCangrelor
Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor
P2RY12Phase 4Coronary Arterial Disease (CAD)Sep 2027
Corewell Health WestClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 4Peripheral Arterial DiseaseOct 2027
Insel Gruppe AG, University Hospital BernP2Y12 inhibitor
P2Y12 receptor antagonist
P2RY12Phase 4Percutaneous Coronary Intervention (PCI)Dec 2027
Zunyi Medical CollegeClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 4ACS - Acute Coronary SyndromeApr 2028
Yonsei UniversityZastaprazan
P2Y12 receptor antagonist
P2RY12Phase 4Chronic Coronary SyndromeJul 2028
Rikke SorensenClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 4Myocardial InfarctionDec 2028
Seoul National University HospitalClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 4Coronary Artery Disease; Antiphospholipid SyndromeDec 2028
Yonsei UniversityClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 4StrokeJul 2029
Todd C. Lee MD MPH FIDSAClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 4Staphylococcus Aureus EndocarditisJan 2030
Federico II UniversityCangrelor
Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor
P2RY12Phase 4Coronary Artery Disease–
Jiangsu vcare pharmaceutical technologyVicagrel
P2Y12 receptor antagonist
P2RY12Phase 3Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)Dec 2026
iVascular S.L.U.1-month DAPT
Dual antiplatelet therapy (acetylsalicylic acid + prasugrel or ticagrelor) for 1 month, fo
P2RY12, TBXA2RPhase 3Coronary Artery DiseaseJan 2027
Ottawa Heart Institute Research CorporationClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 3Cardiac Allograft VasculopathyMar 2027
Fondation Hôpital Saint-JosephClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 3CLTI Defined as Rutherford Category 4 or 5May 2030
Aarhus University HospitalClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 3Covert Brain InfarctionSep 2031
Kafrelsheikh UniversityClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 3Ischemic Stroke–
Kafrelsheikh UniversityTicagrelor
Purinergic receptor P2Y12 negative allosteric modulator
P2RY12Phase 3Ischemic Stroke–
St. Antonius HospitalClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 2Acute Coronary SyndromeJan 2027
University of Sao PauloClopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 2Assessment of Platelet Aggregability in Patients Patients with Non-small Cell Lung CarcinomaOct 2027
University Hospital, Bordeauxclopidogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 2SclerodermaJun 2032
IRCCS San RaffaeleCangrelor
Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 inhibitor
P2RY12Phase 2Cardiogenic Shock–
Mazandaran University of Medical SciencesTicagrelor
Purinergic receptor P2Y12 negative allosteric modulator
P2RY12Phase 2Ischemic Stroke–
Viatris InnovationSelatogrel
Purinergic receptor P2Y12 antagonist
P2RY12Phase 1Chronic Coronary Syndrome–

Conditions

Coronary Artery Disease (8) Ischemic Stroke (5) Coronary Arterial Disease (CAD) (3) Chronic Coronary Syndrome (2) Peripheral Arterial Disease (1) Scleroderma (1) Silent Brain Infarction (1) Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) (1) Covert Brain Infarction (1) Intracranial Arteriosclerosis (1) Acute Coronary Syndrome (1) Percutaneous Coronary Intervention (PCI) (1)

Modalities

small molecule (26), other (1)

Companies

University of Florida (4) Kafrelsheikh University (2) Yonsei University (2) iVascular S.L.U. (1) Corewell Health West (1) University Hospital, Bordeaux (1) VA Office of Research and Development (1) Jiangsu vcare pharmaceutical technology (1) Mazandaran University of Medical Sciences (1) Aarhus University Hospital (1) St. Antonius Hospital (1) Insel Gruppe AG, University Hospital Bern (1) Zunyi Medical College (1) Ottawa Heart Institute Research Corporation (1) Seoul National University Bundang Hospital (1) IRCCS San Raffaele (1) Seoul National University Hospital (1) Rikke Sorensen (1) Todd C. Lee MD MPH FIDSA (1) Federico II University (1)

Related targets

TBXA2R (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.